H eart failure is a major cause of mortality and morbidity. 1 It is associated with Ͼ270 000 deaths in the United States alone. 1 Primary dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are prototypic genetic forms of systolic and diastolic heart failure, respectively. Molecular genetic studies have led to partial elucidation of causal genes and identification of several hundred mutations in families and cases with cardiomyopathies. [2] [3] [4] [5] Accordingly, mutations in genes coding for sarcomere and cytoskeletal proteins have emerged as important causes of primary cardiomyopathies. [2] [3] [4] [5] Genetic studies also have highlighted the genetic heterogeneity of cardiomyopathies, particularly for DCM. 3, 4 Accordingly, the most common known gene for DCM account for Ϸ5% of all primary HCM cases. 4 Collectively, the known causal genes are responsible for approximately two-thirds of HCM families and a much smaller fraction of DCM families. 4, 5 Thus, the causal genes for a significant number of HCM and DCM cases and families remain to be identified.
Clinical Perspective on p 358
The conventional approach for identification of the causal genes for single-gene disorders is genetic linkage analysis. However, the approach does not provide sufficient resolution to identify the causal mutations in small families or sporadic cases. Direct DNA sequencing of the candidate genes, particularly in view of the recent advances in DNA sequencing technologies, is an alternative approach that is being used increasingly to identify the causative mutations/genes. Among the candidate genes for cardiomyopathies are genes encoding the Z-disc proteins. 6, 7 We recently identified and characterized Muscle-Restricted Coiled-Coil (MURC), which encodes a Z-line component protein. 8, 9 We showed that MURC activates the RhoA/ROCK pathway and expression of atrial natriuretic peptide (ANP) and regulates myofiber organization. 8 MURC is also a member of the cavin complex, associated with sarcolemmal caveaolae of muscle cells. 10 Subcellular distribution of MURC is altered in myopathic fibers. 10 Collectively, the experimental data implicate MURC as a biologically plausible gene for human cardiomyopathies. 10 To delineate the causal role of MURC in cardiomyopathies, we sequenced the coding regions and the splice junctions of MURC in 690 cases with cardiomyopathies and 509 control subjects, and, whenever available, we extended the genetic analysis to family members. We complemented the genetic studies with in vitro functional studies in cardiac myocytes. The findings, collectively, implicate MURC as a novel gene for DCM.
Methods

Study Population
The study protocol was approved by the institutional review board and was in accord with the Human Subjects Committee guidelines. The participating individuals signed informed consent. The main study population comprised 383 cases with DCM, 307 cases with HCM, and 277 normal individuals. 7 We obtained phenotypic data, including 12-lead ECGs and echocardiograms in all participants. Cardiomyopathies were diagnosed according to the conventional criteria. 11 Given the relatively small number of the African Americans in the main control group, we included a second group of 232 African Americans who had normal ECGs and echocardiograms. 12 On identification of a putative mutation, defined as insertion/deletion or frame-shift, nonsynonymous, or splice sequence variants, we recruited and phenotyped additional family members whenever available.
DNA Sequencing
We sequenced all exons and exon-intron boundaries of MURC in 1199 participants by the Sanger method in sense and antisense directions (primer sequence is provided in online-only Data Supplement Table I ), using the Big Dye Terminator Reactions in an Applied Biosystems 3730xl Genetic Analyzer (Applied Biosystems, Inc, Foster City, CA). We analyzed the output using Variant Reporter software (Applied Biosystems, Inc). In addition, 2 investigators analyzed every sequence printout to detect the variants. We compared the sequence with the published GenBank sequence for MURC (GRCh37 reference genome assembly, chromosome 9, region 103340336.103350180). To reduce the possibility of sequencing errors, we repeated the sequencing reactions in all samples that contained a sequence variant. Only variants that were detected in sense and antisense directions and confirmed in independent sequencing reactions were considered as real variants.
Mutation Calling
To ascertain a causal role, we analyzed segregation of the variants with the phenotype in the families whenever available and analyzed evolutionary conservation of the involved amino acid using PRRN (http://align.genome.jp/prrn/), charge change, and hydropathy index. We used PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/index.shtml) to predict functional effects of the variants. 13 Nonsynonymous variants that were present only in the cases with cardiomyopathies but absent in the normal control subjects were considered likely disease-causing mutations and selected for in vitro functional studies.
Sequencing of Known Common Causal Genes for Cardiomyopathies
We sequenced the coding regions and exon-intron boundaries of LMNA, encoding Lamin A/C, a known gene for DCM in 103 proband with a compound phenotype of DCM and conduction defect and/or atrial fibrillation. 4 Likewise, we had previously sequenced all exons and exon-intron boundaries of MYH7, MYBPC3, ACTC1, TNNT2, TNNI3, TPM1, and MYOZ2 in 81 probands with familial HCM. Finally, to detect compound mutations in those who carried a mutation in MURC, we sequenced MYH7, MYBPC3, TNNT2, TNNI3, TPM1, ACTC1, and LMNA, known as relatively common genes for HCM and DCM in all MURC mutation carriers. 5, 14, 15 
Genotyping for Short Tandem Repeat Markers
To determine whether the recurring mutations occurred de novo or shared a common ancestral allele, we genotyped the individuals for 3 short tandem repeat (STR) markers (D9S180, D9S910, and D9S176) that spanned an approximately 2.5-Mbp genomic region on 9q31.1 locus. Genotyping was performed by polymerase chain reaction (PCR), using fluorescent-labeled primers and capillary electrophoresis on an ABI 3730xl Genetic Analyzer and analyzed using the GeneMapper v4.1 (Applied Biosystems).
Plasmid Constructs
We cloned human FLAG-tagged MURC cDNA into a pcDNA3.1 vector (pcDNA3.1-hMURC). We introduced the p.N128K, p.R140W, p.L153P, p.S307T, p.P324L, and p.S364L mutations by site directed mutagenesis. 8 Sequences of mutant-specific oligonucleotide primers are shown in online-only Data Supplement Table I .
Isolation and Culture of Neonatal Rat Cardiac Myocytes
We isolated and prepared neonatal rat cardiac myocytes (NRCM) from 1-day-old Sprague-Dawley rats as described. 8 Briefly, we digested ventricular tissues enzymatically and separated cardiac myocytes over a Percoll gradient. We changed the culture medium to serum-free medium after 24 hours and maintained the cells under serum-free conditions before experiments.
Replication-Deficient Recombinant Adenoviruses and Gene Transfer
We generated recombinant adenoviruses expressing FLAG-tagged human wild-type (Ad-hMURC-WT), each of the mutant MURC protein or ␤-galactosidase (Ad-LacZ), as described previously. 8 The Ad-LacZ and Ad-hMURC-WT served as controls. We infected the NRCM with the recombinant adenoviruses at a multiplicity of infection of 10. After incubation at 37°C for 1 hour, the viral suspension was removed, and cells were cultured with serumdepleted culture media for 48 hours.
Immunoblotting
To detect expression of the WT or mutant MURC, we electrophoresed the cell lysates in 10% SDS-polyacrylamide gels and transferred the proteins to polyvinylidene difluoride membranes (Millipore, Billerica, MA). We incubated the membranes with primary antibodies against FLAG (SIGMA, St Louis, MO) and GAPDH to detect FLAG-tagged MURC and GAPDH proteins, respectively. The secondary antibody was horseradish peroxidase-conjugated antimouse IgG (GE Healthcare, Waukesha, WI).
RhoA Activation Assay
We determined RhoA activity in the protein extracts from NRCM transduced with the recombinant adenoviruses using an absorbance-based G-LISA RhoA activation assay biochemistry kit (Cytoskeleton, Denver, CO), as described. 8 We isolated total protein 2 days after transduction of NRCM with the recombinant adenoviruses per instruction of the manufacturer. We equalized the total protein concentrations among the samples at 1 mg/mL for the assay and measured the signals at an absorbance of 490 nm, using a microplate spectrometer.
RNA Extraction and Quantitative Reverse Transcriptase-PCR
We isolated total cellular RNA from NRCM using an RNeasy Mini Kit (QIAGEN, Inc). We performed quantitative reverse transcriptase-PCR (qPCR) to quantify mRNA expression levels of rat ANP (Nppa), B-type natriuretic peptide (BNP or Nppb), and rat skeletal ␣-actin (SkA or Acta1) in NRCM transduced with WT or mutant MURC constructs, as described. 8 Sequences of oligonucleotide primers are shown in online-only Data Supplement Table I .
Cardiac Myocyte Size
Cardiac myocytes were infected with the recombinant adenoviruses and cultured under serum-free conditions for 48 hours. Cells were then fixed with 4% paraformaldehyde and stained with fluorescein isothiocyanate-conjugated phalloidin (SIGMA) for the detection of actin filaments. DNA was stained with 4Ј,6-diamidino-2phenylindole. We measured myocyte surface area using Image software (National Institutes of Health, Bethesda, MD) in at least 100 cells per group.
Statistics
Statistical analyses were similar to those published recently. 7, 16 We expressed the continuous variables that followed normality distribu-tion as meanϮSD. We compared differences among the continuous variables that satisfied the normality distribution by 1-way ANOVA and applied the Bonferroni correction to multiple-comparison tests. Variables that were not normally distributed were compared by Kruskal-Wallis test. We analyzed differences in the categorical variables by 2 test.
All in vitro experiments were performed at least 3 times, and the mean values of the 3 measurements were used. Data are expressed as meanϮstandard error and analyzed by 1-way ANOVA with Scheffe post hoc analysis. A value of PϽ0.05 was considered significant. All statistical analyses were performed using STATA v 10.1.
Results
Characteristics of the Study Population
Phenotypic characteristics of the study population are shown in Table 1 and are partly published. 7, 12 
MURC Sequence Variants
We found 6 DCM-specific heterozygous missense variants (p.N128K, p.R140W, p.L153P, p.S307T, p.P324L, and p.S364L) in 8 probands (Table 2) . These variants were absent in 509 normal individuals. The p.N128K variant cosegregated with DCM in 2 affected family members and was absent in 5 unaffected family members ( Figure 1 ). The p.S307T was present in 4 adult family members, of whom 3 had severe DCM (Figure 1 ). One young adult (31 years old) and 1 child also had the p.S307T variant, whereas 3 phenotypically normal adults had the WT genotype. Segregation analysis that includes healthy individuals in cardiomyopathies is subject to age-dependent and incomplete penetrance. The absence of a clinical phenotype in young mutation carriers in this family may reflect partial and age-dependent penetrance of the variant. Collectively, the p.N128K and p.S307T variants were present in 5 affected family members and absent in 8 of 9 clinically normal members ( 2 ϭ8.5, Pϭ0.003). The small size of these 2 families and the incomplete penetrance of the p.S307T variant impeded the power to calculate the logarithm of odds score, as a measure of linkage to strengthen the causal role of these variants. The p.P324L was a recurring variant, as it was detected in 3 probands. To determine whether the probands shared a common ancestral allele at the MURC locus, we genotyped the 3 families for 3 locus-specific STR markers. The 3 probands did not share the genotypes for the MURC locus, indicating independent origins of the mutation in these individuals (online-only Data Supplement Figure I) .
We also detected a deletion variant (p.L232-R238del), which excluded 7-amino acid-long motif (ERLRQSG, Swiss-Prot ID: Q5BKX8.2) in 3 probands with HCM, 1 African American, and 2 white subjects. The deletion was absent in Ͼ500 control individuals. Two affected members of a HCM family had the deletion variant. However, it was absent in an affected member of another family with the deletion variant (online-only Data Supplement Figure II) . The 2 affected family members in the latter family had a p.L907V mutation in MHY7, a known gene for cardiomyopathies. 5 The p.L907V mutation was absent in Ͼ500 normal individuals, and affects a highly conserved domain in MYH7 protein. It is predicted to be probably damaging by PolyPhen-2 analysis (score, 0.954; sensitivity, 0.74; specificity, 0.93).
In contrast to 7 phenotype-specific variants, we detected only one nonsynonymous variant (p.R272H) that was present only in the control group ( Table 2 ). The p.R272H was predicted to be a benign variant by PolyPhen-2 analysis. To test whether MURC was a disease-causing gene, we per-formed a gene-centric analysis by coalescing the nonsynonymous variants in each group and comparing the prevalence of MURC variants in cases with DCM and control subjects. In support of a causal role of MURC variants in DCM, nonsynonymous variants were overrepresented by 25-fold in the cases (Pearson 2 ϭ7.84, Pϭ0.005).
As would be expected, we identified several polymorphisms that were common to the cases and the control subjects, including 6 nonsynonymous variants, 14 synonymous, and 8 noncoding variants (online-only Data Supplement Tables II and III) . The frequencies of the nonsynonymous or synonymous polymorphisms were not significantly different between the cases and control subjects. Likewise, the age distributions of the control individuals and the DCM cases with the nonsynonymous variants were similar. Overall, the minor allele frequencies of the nonsynonymous polymorphisms were Ͻ1% in the study population. The most common variant was the p.S78L, which had a minor allele frequency of 0.009 in the entire population and 0.033 in the African American subpopulation. The p.N81K was detected in 3 African Americans, 1 with HCM, 1 with DCM, and 1 normal individual. In each case, it cosegregated with the p.S78L variant.
Mutations in Known Genes for Cardiomyopathies
We sequenced all coding regions and exon-intron boundaries of MYH7, MYBPC3, TNNT2, TNNI3, TPM1, ACTC1, and LMNA, known relatively common genes for cardiomyopathies, 4, 5 in all MURC mutation carriers. An African American patient with DCM had a compound mutation: the p.P324L variant in MURC and a novel nonsynonymous variant p.M245T in the TPM1 gene. Likewise, 1 family member who had the p.L232-R238del variant in MURC also had a p.L907V mutation in the MYH7 gene (probably compound mutation).
We identified 3 nonsynonymous variants in LMNA on screening of 103 probands with DCM associated with conduction defect and/or atrial fibrillation. 4 None had a MURC mutation. Likewise, we identified 32 different mutations in MYH7 (14 mutations), MYBPC3 (11 mutations), TNNT2 (2 mutations), TNNI3 (1 mutation), TPM1 (2 mutations), and MYOZ2 (2 mutations) in screening of 81 probands with HCM. None had a mutation in MURC gene.
Phenotypic Expression of MURC Mutation Carriers
The phenotype in the mutation carriers was notable for heart failure in the middle age (mean age, 45.0Ϯ6.5 years), leading to severely depressed left ventricular systolic function, which led to cardiac transplantation in 4 affected members. Cardiac tissues were not available to analyze histological correlates of MURC variants. Several affected members exhibited supraventricular arrhythmias and progressive conduction defects, requiring implantation of a permanent pacemaker and internal cardioverter/defibrillator. Detailed phenotypic data are shown in Table 3 .
Predicted Pathogenicity of the Variants
Conservation of the involved codon and domain across paralogous proteins from zebrafish to humans, a potential indicator of the biological significance of the codon, is shown in Figure 2 . Likewise, the predicted effects of the nonsynonymous variants on MURC protein are shown in Table 4 . Codon N128K affected a totally conserved amino acid from zebrafish to human and had a very high PolyPhen-2 prediction score (0.980; sensitivity, 0.69; specificity, 0.94), placing it in the probably damaging category (highest category). 13 The L153P also affected a highly conserved amino acid from rat (Rattus norvegicus) to human and was categorized as probably damaging (score, 0.975; sensitivity, 0.70; specificity, 0.94). The p.R140W and p.S364L involved conserved amino acids and were predicted to be possibly damaging (score for p.R140W, 0.840; sensitivity, 0.80; specificity, 0.90 and score for p.S364L, 0.438; sensitivity, 0.438; specificity, 0.86). In contrast, p.S307T and p.P324L involved fewer or nonconserved amino acids and were predicted to be benign.
Functional Characterization of MURC Mutations
We have previously shown that MURC activates the RhoA/ ROCK pathway and its downstream target, ANP. 8 Therefore, we transduced NRCM with recombinant viruses expressing either a WT or a mutant MURC protein and measured RhoA activity. Expression of the WT MURC increased RhoA activity by Ϸ80%, a finding that is in accord with the previous data. 8 In contrast, RhoA activity was significantly less in myocytes expressing the mutant MURC proteins as compared with the WT MURC group (Figure 3) .
Likewise, expression of the WT MURC significantly increased mRNA levels of ANP (Nppa) and SkA (Acat1) by Ͼ5-fold and that of BNP (Nppb) by Ϸ2.6-fold (Figure 3) . In contrast, mRNA levels of the Nppa, Nppb, and Acta1 in NRCM transduced with the mutant MURC recombinant viruses were attenuated significantly, as compared with WT MURC. The findings indicate that the mutations impart a loss-of-function effect on the activation of RhoA and expression of the hypertrophic markers by MURC.
To further characterize the phenotypic consequence of the MURC mutations in vitro and complement the data on RhoA activity and expression of the molecular markers of hypertrophy, we measured the effects of expression of WT and mutant MURC proteins on cardiac myocyte size. Expression of the WT MURC increased cardiac myocyte surface area by Ϸ3.5-fold. However, the mutant MURC had attenuated hypertrophic effects, as myocyte surface area was significantly less in the mutant groups as compared with the WT MURC group (Figure 4 ).
Discussion
We have identified 6 DCM-specific heterozygous missense variants, including 4 that were predicted to be probably or possibly pathogenic. The mutations were associated with progressive heart failure, conduction defects, and cardiac arrhythmias. In vitro functional studies indicate loss-offunction effects of the mutant MURC proteins on activation of RhoA, expression of hypertrophic markers, and myocyte hypertrophy. Collectively, human molecular genetic and in vitro functional data implicate MURC as a causal gene for human DCM.
Several lines of evidence support the causal role of MURC mutations in DCM. All 6 nonsynonymous variants were The mutation and wild-type codons are listed under those members that were studied. Individual III-3, who is 31 years old, is a mutation carrier but is phenotypically normal (nonpenetrance). Individual IV-1 in Pedigree F018 is 5 years old and noncontributory to cosegregation analysis. absent in Ͼ500 control individuals who had no clinical, ECG, or echocardiographic evidence of cardiomyopathies. The variants were also absent in the dbSNP (build 132). A gene-centric analysis showed that the missense variants were overrepresented in patients with DCM by 25-fold. Likewise, 2 mutations cosegregated with the phenotype, albeit in small families. Although the de novo recurring mutations in cases only imply a causal role in DCM, the p.P324L recurring variant affected a nonconserved amino acid and was predicted to be benign by PolyPhen-2 analysis. Functional data, assessed at multiple levels, showed concordant results and indicated loss-of-function effects of the MURC mutations. Furthermore, 4 variants either involved largely conserved paralogous codons and/or were predicted to affect structure and biological function of the encoded protein. The findings are also in accord with the in vitro and in vivo biological functions of MURC protein and its potential involvement in myopathic conditions. 8 -10 MURC is a biologically plausible candidate gene for cardiomyopathies. MURC is a Z-line component protein that is predominantly expressed in the heart. 8 -10 Mutations in genes encoding sarcomere and cytoskeletal proteins are major causes of cardiomyopathies. 4, 5 MURC is involved in muscle protein homeostasis through regulating RhoA/ROCK and association with a multiprotein complex at the caveolae. 8 -10 MURC interacts with extracellular signal-related kinases, RhoA/ROCK, and serum response factor pathways, which are also implicated in heart failure. 8, 9, 17 RhoA appears to play a delicate role in regulating cardiac function because its overexpression or its inhibition results in conduction defects and cardiac dysfunction. 18, 19 Likewise, cardiac-restricted overexpression of MURC in mice leads to heart failure, conduction defect, and atrial arrhythmias. 8 Moreover, MURC is a component of a multiprotein complex in the caveolae that regulates cardiac function. 10 Its subcellular distribution is perturbed in human muscle disease associated with Caveolin-3 dysfunction. 10 Notably mutations in CAV3, encoding caveolin 3, are also known to cause cardiac and skeletal myopathy. 20, 21 The causal role of the MURC deletion mutation in HCM is less clear. Evidence in support of a potential causal role includes recurrence in 2 different ethnic populations and hence, occurring independently, its absence in Ͼ500 normal individuals and the increasing recognition of prevalence of compound mutations in cardiomyopathies. [22] [23] [24] [25] However, the deletion variant was not present in an affected family member with the phenotype and hence, conventionally cannot be considered a causal variant in this family. The 2 affected members in this small family also had a missense mutation (p.L907V) in MYH7, which is predicted to be probably damaging. It is possible that the deletion variant codependently contributes to phenotypic expression of HCM in this family. These findings highlight the challenge of establishing the causal role of the DNA sequence variants in sporadic cases and small families, as opposed to large families, wherein cosegregation of the phenotype with inheritance of the variants (genetic linkage) could support the causality. While the actual LOD score is determined by the family structure and information content of the locus markers, typically Ͼ7 affected family members are necessary to achieve a significant LOD score in a linkage analysis of a familial disease with an autosomal dominant mode of inheritance, assuming 100% penetrance. Unfortunately, neither the number of the affected individuals in our families is adequate nor the penetrance is complete to perform a meaningful linkage analysis. The challenge is expected to have considerable clinical implications, as whole-exome or wholegenome sequencing gains clinical applications. The task is daunting because each diploid human genome contains Ͼ10 000 nonsynonymous variants, the majority of which are not associated with any discernible clinically phenotype (discussed in Reference 26). 26 Accordingly, several lines of genetic and functional data must be incorporated in discerning clinical significance of the DNA sequence variants in , wild-type human MURC (Ad-hMURC-WT), and each of the specific mutant MURCs (Ad-N128K, Ad-R140W, Ad-L153P, Ad-S307T, Ad-P324L, or Ad-S364L) that were identified in patients with dilated cardiomyopathy (DCM) (nϭ3 independent experiments per group. B, C, and D, MicroRNA expression levels of atrial natriuretic peptide (ANP; gene, Nppa), B-type or brain natriuretic peptide (BNP; gene name, Nppb), and skeletal ␣-actin (SkA; gene name, Acta1) in cardiac myocytes transduced at an MOI of 10 with control recombinant adenoviruses or viruses expressing WT or each of the 6 mutant MURC proteins. Cells were harvested 48 hours after the infection for extraction of RNA and quantitative reverse transcriptase-polymerase chain reaction. E, Immunoblot of myocytes proteins extracted 48 hours after transduction with the recombinant viruses and probed with an anti-FLAG antibody to detect expression of the WT or mutant MURC proteins (upper blot). Immunoblotting was performed to assess equal expression level of the WT and mutant MURC proteins among the groups. The lower blot shows expression of GAPDH, which was used as a control for loading conditions. *PϽ0.05 and **PϽ0.01 as compared with WT MURC.
sporadic cases or small families. Although our data strongly support the causal role of the MURC variants in DCM, one must consider the possibility that the MURC variants may not be true disease-causing variants but are susceptibility alleles that require a second mutation or injury to cause the clinical phenotype. There is also a possibility that these variants are functional variants that do not play significant roles in susceptibility to cardiomyopathies. We submit that the strengths of the genetic and functional data favor the causal role of MURC variants in the pathogenesis of human cardiomyopathies. 
